Topic

Lisa Henderson is the group editorial director of 

 and can be reached at lhenderson@mjhlifesciences.com.

Articles

While ESG is still in the early stages for pharma, many companies are moving forward with a need for compliance.

Checklist compliance clipboard | Image Credit: © Andrii - stock.adobe.com

PCC 2023: ESG, New Turf for Compliance

is head of external affairs and ESG at Organon. In this role, she focuses on guiding and shaping how the company interacts with key stakeholders and the environment.

Examining efforts to boost women representation on company boards.

Pharma Governance and the Quest for Gender Equity

The validity of ESG-driven investment and reporting in healthcare.

Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?

Corporate Vice President, Global Public Affairs and Sustainability, Novo Nordisk

Reaching new heights in sustainability a win-win for industry.

Healthy Planet, Healthy People: How Pharma Can Lead the Way

Executive Vice President, Pharma, at Informa – the event organizer behind CPHI Frankfurt

Pharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology.

At the Heart of Pharma: ESG has Arrived as a Central Strategy

Dr. Pamela Walker is Global Head of Health at Kin + Carta Advise.

A prime opportunity for pharma to raise its strategic game in ESG.

ESG: Applying  Lessons From Consumer Market 

Adam Carter discusses the causes and potential solutions to the pharma industry's sustainability issues.

Q&A with Adam Carter, global product manager for Thermo Fisher Scientific

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

Elevating ESG Message: Today’s Modern Investor is Key

How principles of both can help companies navigate future storms.

Meeting the Moment: ESG Strategy and the Business of Resilience

Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet 
new expectations in advancing this strategic mandate.